Cardiovascular Risk Factors and Clinical Outcomes among Patients Hospitalized with COVID-19: Findings from the World Heart Federation COVID-19 Study.
COVID-19
cardiovascular disease
mortality
Journal
Global heart
ISSN: 2211-8179
Titre abrégé: Glob Heart
Pays: England
ID NLM: 101584391
Informations de publication
Date de publication:
2022
2022
Historique:
received:
13
03
2022
accepted:
19
05
2022
entrez:
15
7
2022
pubmed:
16
7
2022
medline:
19
7
2022
Statut:
epublish
Résumé
Limited data exist on the cardiovascular manifestations and risk factors in people hospitalized with COVID-19 from low- and middle-income countries. This study aims to describe cardiovascular risk factors, clinical manifestations, and outcomes among patients hospitalized with COVID-19 in low, lower-middle, upper-middle- and high-income countries (LIC, LMIC, UMIC, HIC). Through a prospective cohort study, data on demographics and pre-existing conditions at hospital admission, clinical outcomes at hospital discharge (death, major adverse cardiovascular events (MACE), renal failure, neurological events, and pulmonary outcomes), 30-day vital status, and re-hospitalization were collected. Descriptive analyses and multivariable log-binomial regression models, adjusted for age, sex, ethnicity/income groups, and clinical characteristics, were performed. Forty hospitals from 23 countries recruited 5,313 patients with COVID-19 (LIC = 7.1%, LMIC = 47.5%, UMIC = 19.6%, HIC = 25.7%). Mean age was 57.0 (±16.1) years, male 59.4%, pre-existing conditions included: hypertension 47.3%, diabetes 32.0%, coronary heart disease 10.9%, and heart failure 5.5%. The most frequently reported cardiovascular discharge diagnoses were cardiac arrest (5.5%), acute heart failure (3.8%), and myocardial infarction (1.6%). The rate of in-hospital deaths was 12.9% (N = 683), and post-discharge 30 days deaths was 2.6% (N = 118) (overall death rate 15.1%). The most common causes of death were respiratory failure (39.3%) and sudden cardiac death (20.0%). The predictors of overall mortality included older age (≥60 years), male sex, pre-existing coronary heart disease, renal disease, diabetes, ICU admission, oxygen therapy, and higher respiratory rates (p < 0.001 for each). Compared to Caucasians, Asians, Blacks, and Hispanics had almost 2-4 times higher risk of death. Further, patients from LIC, LMIC, UMIC versus. HIC had 2-3 times increased risk of death. The LIC, LMIC, and UMIC's have sparse data on COVID-19. We provide robust evidence on COVID-19 outcomes in these countries. This study can help guide future health care planning for the pandemic globally.
Sections du résumé
Background and aims
Limited data exist on the cardiovascular manifestations and risk factors in people hospitalized with COVID-19 from low- and middle-income countries. This study aims to describe cardiovascular risk factors, clinical manifestations, and outcomes among patients hospitalized with COVID-19 in low, lower-middle, upper-middle- and high-income countries (LIC, LMIC, UMIC, HIC).
Methods
Through a prospective cohort study, data on demographics and pre-existing conditions at hospital admission, clinical outcomes at hospital discharge (death, major adverse cardiovascular events (MACE), renal failure, neurological events, and pulmonary outcomes), 30-day vital status, and re-hospitalization were collected. Descriptive analyses and multivariable log-binomial regression models, adjusted for age, sex, ethnicity/income groups, and clinical characteristics, were performed.
Results
Forty hospitals from 23 countries recruited 5,313 patients with COVID-19 (LIC = 7.1%, LMIC = 47.5%, UMIC = 19.6%, HIC = 25.7%). Mean age was 57.0 (±16.1) years, male 59.4%, pre-existing conditions included: hypertension 47.3%, diabetes 32.0%, coronary heart disease 10.9%, and heart failure 5.5%. The most frequently reported cardiovascular discharge diagnoses were cardiac arrest (5.5%), acute heart failure (3.8%), and myocardial infarction (1.6%). The rate of in-hospital deaths was 12.9% (N = 683), and post-discharge 30 days deaths was 2.6% (N = 118) (overall death rate 15.1%). The most common causes of death were respiratory failure (39.3%) and sudden cardiac death (20.0%). The predictors of overall mortality included older age (≥60 years), male sex, pre-existing coronary heart disease, renal disease, diabetes, ICU admission, oxygen therapy, and higher respiratory rates (p < 0.001 for each). Compared to Caucasians, Asians, Blacks, and Hispanics had almost 2-4 times higher risk of death. Further, patients from LIC, LMIC, UMIC versus. HIC had 2-3 times increased risk of death.
Conclusions
The LIC, LMIC, and UMIC's have sparse data on COVID-19. We provide robust evidence on COVID-19 outcomes in these countries. This study can help guide future health care planning for the pandemic globally.
Identifiants
pubmed: 35837356
doi: 10.5334/gh.1128
pmc: PMC9205371
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
40Subventions
Organisme : FIC NIH HHS
ID : K43 TW011164
Pays : United States
Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright: © 2022 The Author(s).
Déclaration de conflit d'intérêts
The authors have no competing interests to declare.
Références
Eur Heart J. 2020 May 14;41(19):1798-1800
pubmed: 32186331
JAMA Intern Med. 2020 Oct 1;180(10):1345-1355
pubmed: 32667669
Eur J Integr Med. 2020 Dec;40:101226
pubmed: 33101547
Am J Epidemiol. 2003 May 15;157(10):940-3
pubmed: 12746247
Ann Med. 2021 Dec;53(1):227-236
pubmed: 33345626
Lancet Infect Dis. 2020 Jun;20(6):669-677
pubmed: 32240634
J Epidemiol Glob Health. 2021 Mar;11(1):98-104
pubmed: 33095982
Am J Epidemiol. 2004 Apr 1;159(7):702-6
pubmed: 15033648
Postgrad Med J. 2021 May;97(1147):312-320
pubmed: 32978337
Am J Med Sci. 2021 Jan;361(1):14-22
pubmed: 33187633
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Nat Rev Cardiol. 2020 Sep;17(9):543-558
pubmed: 32690910
JAMA. 2020 Apr 28;323(16):1549-1550
pubmed: 32176764
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Front Med (Lausanne). 2021 May 12;8:623608
pubmed: 34055822
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
Afr J Urol. 2021;27(1):89
pubmed: 34230799
Pol Arch Intern Med. 2020 Apr 30;130(4):304-309
pubmed: 32231171
PLoS One. 2020 Nov 3;15(11):e0241742
pubmed: 33141836
JAMA Netw Open. 2021 Oct 1;4(10):e2130479
pubmed: 34673962
Am J Cardiol. 2021 May 1;146:99-106
pubmed: 33539857
Clin Infect Dis. 2020 Nov 19;71(16):2199-2206
pubmed: 32407459
Nature. 2021 Feb;590(7844):140-145
pubmed: 33137809
Acta Pharm Sin B. 2021 Jan;11(1):1-12
pubmed: 33072500
J Am Coll Cardiol. 2020 Apr 7;75(13):1551-1561
pubmed: 32241371
Stud Health Technol Inform. 2019 Aug 21;264:1635-1636
pubmed: 31438267
Clin Infect Dis. 2021 Dec 16;73(12):2193-2204
pubmed: 33608710
Heart Lung Circ. 2020 Jul;29(7):973-987
pubmed: 32601020
JAMA. 2013 Oct 23;310(16):1711-20
pubmed: 24150467
Ethn Dis. 2021 Jul 15;31(3):389-398
pubmed: 34295125
Lancet. 2020 Oct 3;396(10256):991-1044
pubmed: 32941823
BMJ. 2020 Apr 7;369:m1328
pubmed: 32265220
Glob Heart. 2020 Apr 09;15(1):31
pubmed: 32489804
J Cardiothorac Vasc Anesth. 2021 Jun;35(6):1860-1865
pubmed: 32451271
Indian J Med Microbiol. 2020 Apr-Jun;38(2):139-143
pubmed: 32883925
JAMA Cardiol. 2020 Jul 1;5(7):802-810
pubmed: 32211816
Am J Epidemiol. 2014 Apr 15;179(8):1034-5
pubmed: 24553682
J Am Coll Cardiol. 2020 Oct 13;76(15):1777-1794
pubmed: 33032740
Biol Reprod. 2020 Aug 21;103(3):449-451
pubmed: 32427288
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
J Am Heart Assoc. 2021 Mar 16;10(6):e019636
pubmed: 33719496
Glob Heart. 2021 Apr 19;16(1):22
pubmed: 34040935
Cell Mol Life Sci. 2021 Jan;78(2):531-544
pubmed: 32780149